Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these...
Saved in:
Published in | Pharmaceutics Vol. 14; no. 2 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
MDPI
01.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these patients. We aimed to describe amikacin pharmacokinetics on V-A ECMO support and to determine relevant variables to improve its dosing. All critically ill patients requiring empirical antimicrobial therapy, including amikacin for nosocomial sepsis supported or not by V-A ECMO, were included in a prospective population pharmacokinetic study. This population pharmacokinetic analysis was built with a dedicated software, and Monte Carlo simulations were performed to identify doses achieving therapeutic plasma concentrations. Thirty-nine patients were included (control n = 15, V-A ECMO n = 24); 215 plasma assays were performed and used for the modeling process. Patients received 29 (24–33) and 32 (30–35) mg/kg of amikacin in control and ECMO groups, respectively. Data were best described by a two-compartment model with first-order elimination. Inter-individual variabilities were observed on clearance, central compartment volume (V1), and peripherical compartment volume (V2). Three significant covariates explained these variabilities: Kidney Disease Improving Global Outcomes (KDIGO) stage on amikacin clearance, total body weight on V1, and ECMO support on V2. Our simulations showed that the adequate dosage of amikacin was 40 mg/kg in KDIGO stage 0 patients, while 25 mg/kg in KDIGO stage 3 patients was relevant. V-A ECMO support had only a secondary impact on amikacin pharmacokinetics, as compared to acute kidney injury. |
---|---|
AbstractList | Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these patients. We aimed to describe amikacin pharmacokinetics on V-A ECMO support and to determine relevant variables to improve its dosing. All critically ill patients requiring empirical antimicrobial therapy, including amikacin for nosocomial sepsis supported or not by V-A ECMO, were included in a prospective population pharmacokinetic study. This population pharmacokinetic analysis was built with a dedicated software, and Monte Carlo simulations were performed to identify doses achieving therapeutic plasma concentrations. Thirty-nine patients were included (control n = 15, V-A ECMO n = 24); 215 plasma assays were performed and used for the modeling process. Patients received 29 (24–33) and 32 (30–35) mg/kg of amikacin in control and ECMO groups, respectively. Data were best described by a two-compartment model with first-order elimination. Inter-individual variabilities were observed on clearance, central compartment volume (V1), and peripherical compartment volume (V2). Three significant covariates explained these variabilities: Kidney Disease Improving Global Outcomes (KDIGO) stage on amikacin clearance, total body weight on V1, and ECMO support on V2. Our simulations showed that the adequate dosage of amikacin was 40 mg/kg in KDIGO stage 0 patients, while 25 mg/kg in KDIGO stage 3 patients was relevant. V-A ECMO support had only a secondary impact on amikacin pharmacokinetics, as compared to acute kidney injury. |
Author | Woerther, Paul-Louis Khoudour, Nihel Mongardon, Nicolas Alessandri, Claire Pressiat, Claire Haouache, Hakim de Roux, Quentin Hutin, Alice Vodovar, Dominique Ghaleh, Bijan Kudela, Agathe Hulin, Anne |
Author_xml | – sequence: 1 givenname: Claire orcidid: 0000-0003-0728-2701 surname: Pressiat fullname: Pressiat, Claire organization: CHU Henri Mondor [Créteil] – sequence: 2 givenname: Agathe surname: Kudela fullname: Kudela, Agathe organization: CHU Henri Mondor [Créteil] – sequence: 3 givenname: Quentin surname: de Roux fullname: de Roux, Quentin organization: CHU Henri Mondor [Créteil] – sequence: 4 givenname: Nihel orcidid: 0000-0002-8269-9817 surname: Khoudour fullname: Khoudour, Nihel organization: CHU Henri Mondor [Créteil] – sequence: 5 givenname: Claire surname: Alessandri fullname: Alessandri, Claire organization: CHU Henri Mondor [Créteil] – sequence: 6 givenname: Hakim surname: Haouache fullname: Haouache, Hakim organization: CHU Henri Mondor [Créteil] – sequence: 7 givenname: Dominique surname: Vodovar fullname: Vodovar, Dominique organization: Optimisation thérapeutique en Neuropsychopharmacologie – sequence: 8 givenname: Paul-Louis surname: Woerther fullname: Woerther, Paul-Louis organization: Groupe Henri Mondor-Albert Chenevier – sequence: 9 givenname: Alice orcidid: 0000-0002-5349-4687 surname: Hutin fullname: Hutin, Alice organization: IMRB - PROTECT/"Pharmacologie et Technologies pour les Maladies Cardiovasculaires" [Créteil] – sequence: 10 givenname: Bijan orcidid: 0000-0003-0061-5462 surname: Ghaleh fullname: Ghaleh, Bijan organization: IMRB - PROTECT/"Pharmacologie et Technologies pour les Maladies Cardiovasculaires" [Créteil] – sequence: 11 givenname: Anne orcidid: 0000-0001-9430-9866 surname: Hulin fullname: Hulin, Anne organization: CHU Henri Mondor [Créteil] – sequence: 12 givenname: Nicolas orcidid: 0000-0003-2756-4052 surname: Mongardon fullname: Mongardon, Nicolas organization: CHU Henri Mondor [Créteil] |
BackLink | https://hal.science/hal-03907439$$DView record in HAL |
BookMark | eNqVj09Lw0AQxRep2Fb7EYS9eojun4jdY5BKDxVzKF7DGKZmbTIbJltpv70b9eDVYWBmHu_9YOZiQoFQiGutbq116q5vgDuo8RB9PehcGWWW7kzMtHMuy52xkz_7VCyG4UOlslYvrbsQU3tvxpSZiaYM_aGF6APJ8oca9p5wBMuwk0Xn91B7kqnLZEOKSSf5ihSygiOyh1aujpFTkPvAmM5n7N4YCOXL8fSO9E2_Euc7aAdc_M5LcfO02j6uswbaqmffAZ-qAL5aF5tq1FR69CG37lPb_3i_AD6iWoI |
ContentType | Journal Article |
Copyright | Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | 1XC |
DOI | 10.3390/pharmaceutics14020289 |
DatabaseName | Hyper Article en Ligne (HAL) |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1999-4923 |
ExternalDocumentID | oai_HAL_hal_03907439v1 |
GroupedDBID | --- 1XC 3V. 53G 5VS 8G5 AADQD ABDBF ABUWG ACGFO ACIHN ADRAZ AEAQA AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AZQEC BENPR BPHCQ CCPQU DIK DWQXO EBD ESX F5P FD6 GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR IPNFZ ITC KQ8 M2O M48 MK0 MODMG M~E OK1 P6G PGMZT PIMPY PQQKQ PROAC RIG RNS RPM TR2 TUS |
ID | FETCH-hal_primary_oai_HAL_hal_03907439v13 |
IEDL.DBID | M48 |
ISSN | 1999-4923 |
IngestDate | Tue Oct 15 14:56:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | amikacin pharmacokinetic/pharmacodynamic modeling extracorporeal membrane oxygenation Bayesian modelization sepsis therapeutic drug monitoring population pharmacokinetics |
Language | English |
License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-hal_primary_oai_HAL_hal_03907439v13 |
Notes | PMCID: PMC8879580 |
ORCID | 0000-0002-5349-4687 0000-0003-2756-4052 0000-0003-0728-2701 0000-0003-0061-5462 0000-0001-9430-9866 0000-0002-8269-9817 0000-0002-8269-9817 0000-0003-0061-5462 0000-0003-2756-4052 0000-0002-5349-4687 0000-0001-9430-9866 0000-0003-0728-2701 |
PMID | 35214022 |
ParticipantIDs | hal_primary_oai_HAL_hal_03907439v1 |
PublicationCentury | 2000 |
PublicationDate | 2022-02 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02 |
PublicationDecade | 2020 |
PublicationTitle | Pharmaceutics |
PublicationYear | 2022 |
Publisher | MDPI |
Publisher_xml | – name: MDPI |
SSID | ssj0000331839 |
Score | 4.55781 |
Snippet | Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount... |
SourceID | hal |
SourceType | Open Access Repository |
SubjectTerms | Life Sciences Toxicology |
Title | Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation |
URI | https://hal.science/hal-03907439 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8NAEB5qBelFfOKzLCIFoVGT3bTJQSSIpYjVHFrprWySLS2129pWaf69M5s-LopCLtlsBpKd7HzfZucbgEsZJZzLOLG8uBpbwu8Ky_MjZVW9xBWJrCATonznxkul3hJPbbedg6WgwuIFTn-kdlRPqjV5v55_pPf4wd8R40TKfjPurVd_pzYRImQRG7DpCC7I6RsLxG8mZ05O7Jt_zT7VV3N4ltfzu6UCbCFKoTMHA1BvueBqAlBtB7YXyJEF2VDvQk7pPSiFma20zJrrTKppmZVYuBalTvehF64qda2uDBBhUm826rJg2B_IuK8ZHmGmtYrtmr0pPbIC2veJjsoe57MJ3kjixwgwWUMNkWxrxV7nKTqisX4AV7XH5kPdwkfojDMtiw6pS9eD5w613XJiytz_svkh5PVIqyNggqvIcx2qFi6FG9tSdUkSLqlKWyicHY7h4m97J__pdAoFh3ILzJboM8jPJp_qHCP-LCoaplw0I_kNFpSxKQ |
link.rule.ids | 230,315,786,790,870,891,24346,27955,27956 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Population+Pharmacokinetics+of+Amikacin+in+Patients+on+Veno-Arterial+Extracorporeal+Membrane+Oxygenation&rft.jtitle=Pharmaceutics&rft.au=Pressiat%2C+Claire&rft.au=Kudela%2C+Agathe&rft.au=de+Roux%2C+Quentin&rft.au=Khoudour%2C+Nihel&rft.date=2022-02-01&rft.pub=MDPI&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=14&rft.issue=2&rft_id=info:doi/10.3390%2Fpharmaceutics14020289&rft_id=info%3Apmid%2F35214022&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai_HAL_hal_03907439v1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon |